Ontario

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission: Policy Directive

The purpose of this notice is to provide information regarding changes to the Template Letter of Consent to assist manufacturers in making submissions to the OHIP, Pharmaceuticals and Devices Division.

Manufacturers are asked to take note of the changes and use the updated Template Letter of Consent effective immediately.

Manufacturers must continue to make submissions to the OHIP, Pharmaceuticals and Devices Division in accordance with the Ontario Guidelines for Drug Submission and Evaluation (the "Guidelines") in order to have their products considered by the Executive Officer for funding under Ontario public drug programs and/or interchangeability under the *Drug Interchangeability and Dispensing Fee Act*, as applicable.

Manufacturers are responsible for monitoring changes made to the Guidelines and the accompanying templates, checklists and worksheets from time to time.

For more information, please refer to the Template Letter of Consent posted on the ministry's website at: Drug Submissions